प्रौद्योगिकी और प्रयोगशाला

Technology: Illumina Sequencing Platform (Microarray Chip)

At tellmeGen, we employ Illumina's sequencing platform, a technology of American origin with leading industry patents, which allows us to analyze over 750,000 genetic markers (SNPs) with exceptional precision. Furthermore, we personalize the analysis by incorporating over 10,000 additional SNPs to enhance specificity and utility in clinical and ancestry applications. To maximize reliability, we duplicate the analyzed probes, elevating the reproducibility and quality of results to the highest industry standards. This ensures detailed and reliable genetic information, ideal for informed decisions in health and well-being.

Broad applications in research and clinical practice

The selected variants optimize imputation with high accuracy for those with an allelic frequency above 1%. We include specific markers that deliver optimal results in health, personal traits, and ancestry, supported by the robustness of Illumina technology.

Global content

Our platform integrates a multi-ethnic backbone that covers the entire genome, with clinical research variants, quality control (QC) markers, and flexibility to incorporate additional content. This inclusive approach ensures relevance for users of diverse ethnic backgrounds.

High-performance workflow

Designed to process thousands of samples weekly in large-scale studies, our technology combines genetic expertise with computational power. This expands the analysis of a DNA chip to tens of millions of variants through imputation, allowing the study of associations with diseases not covered in the initial 750,000 SNPs. Thus, we estimate individual genetic risk with unprecedented accuracy.

Robust, high-quality essay

The tellmeGen chip, based on innovative Illumina technology, offers superior reproducibility of over 99%, ensuring consistent and reliable results in every analysis.